Point-of-care PSA testing: An evaluation of PSAwatch

Prostate Cancer and Prostatic Diseases

Volumn 10, Issue 3, 2007, Pages 270-273

  Karim, O ^a,b   Rao, A ^a   Emberton, M ^b,c   Cochrane, D ^b   Partridge, M ^b   Edwards, P ^b   Walker, I ^a   Davidson, I ^b  

^a WEXHAM PARK HOSPITAL   (United Kingdom)

^b Mediwatch Plc   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONCENTRATION (PARAMETERS); CONSULTATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; HOSPITAL CARE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; POINT OF CARE TESTING; PRIORITY JOURNAL; PROSTATE DISEASE; QUANTITATIVE DIAGNOSIS; REFERENCE VALUE;

HUMANS; MALE; MASS SCREENING; POINT-OF-CARE SYSTEMS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 34548456052     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500962     Document Type: Article

References (16)

1. Ablin RJ, Bronson P, Soanes WA, Witebsky E. Tissue- and species-specific antigens of normal human prostatic tissue. J Immunol 1970; 104 1329-1339.
2. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159-163.
3. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery what we have learned and where we are going. J Urol 1999; 162: 293-306.
4. Roehrborn CG, Malice M, Cook TJ, Girman CJ. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: A comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001; 58: 210-216.
5. Mochtar CA, Kiemeney LA, Laguna UP, van Riemsdijk MM, Barnett GS, Debruyne FM. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alphal-blockers and watchful waiting. Urology 2005, 65: 300-305.
6. D'Ambrosio G, Samani F, Cancian M, De Mola C. Practice of opportunistic prostate-specific antigen screening in Italy: Data from the Health Search database. Eur J Cancer Prev 2004; 13: 383-386.
7. Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R et al. Early outcomes of active surveillance for localized prostate cancer. BJU Int 2005; 95: 956-960.
8. AOU. Action On Urology Good Practice Guide - Outcomes from 32 Action On Urology Sites. NHS Modernisation Agency, p 31. March 2005.
9. Lintz Y, Moynihan C, Steginga S, Norman A, Eeles R, Huddart R et al. Prostate cancer patients' support and psychological care needs: survey from a non-surgical oncology clinic. Psychooncology 2003; 12: 769-783.
10. Milford Ward A, Catto, JWF, Hamdy FC. Prostate specific antigen: biology, biochemistry and available commercial assays. Ann Clin Biochem 2001; 38: 633-651.
11. Blijenberg BG, Yurdakul G, Van Zelst BD, Bangma CH, Wildhagen MF, Schroder FH. Discordant performance of assays for free and total prostate-specific antigen in relation to the early detection of prostate cancer. BJU Int 2001; 88: 545-550.
12. R Development Core Team 2006. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN:H3-900051-07-0, URL: http://www.R-project.org.
13. AOU. Action On Urology Good Practice Guide - Outcomes from 32 Action On Urology Sites. NHS Modernisation Agency, p 4 March 2005.
14. AOU. Action On Urology Good Practice Guide - Outcomes from 32 Action On Urology Sites. NHS Modernisation Agency, p 6. March 2005.
15. Cancer Services Collaborative. Improvement Partnership. http://www.modern.nhs.uk/cancer.
16. Singh R, Cahill D, Popert R, O'Brien TS. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy. BJU Int 2003; 92: 932-935.